Barinthus Biotherapeutics
BRNS
16 hedge funds and large institutions have $29.5M invested in Barinthus Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
48% more capital invested
Capital invested by funds: $20M → $29.5M (+$9.55M)
7% more funds holding
Funds holding: 15 → 16 (+1)
0.36% more ownership
Funds ownership: 25.66% → 26.02% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$32.3K |
| 2 |
Morgan Stanley
New York
|
+$12.4K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.15K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$129 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$276K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.6K |
| 3 |
Renaissance Technologies
New York
|
-$27.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.94K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$47 |
BRNS Hedge Fund Activity: Q3 2023 in Review
16 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q3 2023, worth a combined $29.5M — up 48% from $20M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BRNS positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $32.3K. The largest seller was Liontrust Investment Partners, exiting entirely with an estimated $276K sold.
- 16 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q3 2023, up from 15 in Q2 2023.
- Funds reported $29.5M of Barinthus Biotherapeutics stock for Q3 2023, up 48% quarter-over-quarter.
- 3 funds opened new Barinthus Biotherapeutics positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q3 2023 was Janney Montgomery Scott, an estimated $32.3K added.
- The largest Barinthus Biotherapeutics seller in Q3 2023 was Liontrust Investment Partners, an estimated $276K sold.
Based on aggregated 13F filings for Q3 2023.